Drug intelligence / Profile preview

TETRALITE

Development stage: Phase 2
Lead developer: LiteVax
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**TETRALITE** is an investigational adjuvanted seasonal influenza vaccine developed by LiteVax. The product combines a licensed inactivated seasonal influenza vaccine with LiteVax Adjuvant, a synthetic carbohydrate fatty-acid monosulphate ester formulated on squalane-in-water emulsion nanodroplets. The first-in-human study evaluated one-fifth of the standard licensed-vaccine antigen dose with low or high adjuvant doses; a subsequent study evaluated LiteVax Adjuvant added to a full licensed-vaccine dose in adults and older adults. It is intended to enhance influenza vaccine immunogenicity while potentially reducing antigen requirements. ([litevax.com](https://www.litevax.com/wp-content/uploads/PR-TETRA-LITE.pdf))

Other names: TETRA-LITETETRALITE

Beyond the preview

Go deeper on TETRALITE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TETRALITE.

Explore the full profile